PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
New Survey Reveals that Singaporeans Know More about Dementia But Nearly 7 in 10 are Unsure Where to Seek Help
Third national survey by SMU on dementia found that stigma persists; despite rising awareness, preparedness remains below neutral ...
2026-05-13T    Computer/Electronics   Education   Health Care/Hospital   Higher Education 
Herbalife and Cristiano Ronaldo Bring Performance Nutrition to Everyday Routines with "Fuel Like Ronaldo" Campaign
Backed by more than 20 years of experience fueling elite athletes, Herbalife brings its proven performance nutrition expertise to wellness seekers worldwide ...
2026-05-13T    Beverages   Health Care/Hospital   Sports 
New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function
HONG KONG , May 13, 2026 /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in  Nature Communications , reporting that Efsubaglutide Alfa, a long-acting GLP-1 receptor agonist, ...
2026-05-13T    Health Care/Hospital   Medical/Pharmaceuticals 
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
SHANGHAI , May 13, 2026 /PRNewswire/ --  WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued ...
2026-05-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
SAN FRANCISCO and SUZHOU, China , May 13, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
2026-05-13T    Health Care/Hospital   Medical/Pharmaceuticals 
Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
CHENGDU, China , May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical ...
2026-05-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class
New kit offers researchers and development teams a meaningful advance in expression speed and output ...
2026-05-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
CRANBURY, N.J. and SUZHOU, China , May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products ...
2026-05-12T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. ...
2026-05-12T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk ...
2026-05-12T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.